PATENT CLAIM ANALYSIS

Application Number: 16165194
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["514", "282000"]

Abstract:
The presently described technology provides compositions comprising aryl carboxylic acids and, for example NSAIDs, chemically conjugated to oxycodone (4,5-α-epoxy-14-hydroxy-17-methylmorphinan-6-one) to form novel prodrugs/compositions of oxycodone, including benzoates, salicylates, propionates, fenamates, and acetates, which have a decreased potential for abuse of oxycodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.

Claim (Index 11):
The composition of  claim 3 , wherein the compound is in an amount sufficient to provide a therapeutically equivalent AUC when compared to unconjugated oxycodone after oral, sublingual, transdermal, suppository, intranasal, intravenous, or intrathecal administration.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 97.0
- Lexical Diversity: 1.5102
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14952348', '15812730', '16054578', '15589158', '14956642']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8824737979354045
- 35 USC 102 Novelty (BERT): 0.6863405556431276
- Combined Prediction Score: 0.8628604737061768
- Mean Citation Score: 781.218746
- Max Citation Score: 836.9954
- Similarity Product: 662.5785204721451

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test